Antivirals for COVID-19: A Critical Review

Overview

Journal Clin Epidemiol Glob Health

Specialty Public Health

Date 2021 Feb 1

PMID 33521390

Citations 76

Authors

Andri Frediansyah

Ruchi Tiwari

Khan Sharun

Kuldeep Dhama

Harapan Harapan

Affiliations

Soon will be listed here.

Abstract

No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.

Citing Articles

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.

Barghash R, Gemmati D, Awad A, Elbakry M, Tisato V, Awad K Molecules. 2024; 29(23.

PMID: 39683724 PMC: 11643501. DOI: 10.3390/molecules29235564.

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies.

Muthukutty P, MacDonald J, Yoo S Vaccines (Basel). 2024; 12(11).

PMID: 39591123 PMC: 11598775. DOI: 10.3390/vaccines12111220.

Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.

Mahendran T, Cynthia B, Thevendran R, Maheswaran S Mol Biotechnol. 2024; .

PMID: 39085563 DOI: 10.1007/s12033-024-01240-4.

Molecular modeling of some commercially available antiviral drugs and their derivatives against SARS-CoV-2 infection.

Arman M, Alam S, Maruf R, Shams Z, Islam M Narra J. 2024; 4(1):e319.

PMID: 38798846 PMC: 11125382. DOI: 10.52225/narra.v4i1.319.

Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis.

Fajar J, Ilmawan M, Mamada S, Mutiawati E, Husnah M, Yusuf H Narra J. 2024; 1(3):e48.

PMID: 38450213 PMC: 10914045. DOI: 10.52225/narra.v1i3.48.

References

Wu Y, Xie Y, Wang X . Longitudinal CT Findings in COVID-19 Pneumonia: Case Presenting Organizing Pneumonia Pattern. Radiol Cardiothorac Imaging. 2021; 2(1):e200031. PMC: 7233389. DOI: 10.1148/ryct.2020200031. View

Li Z, Wang Y, Zhu J, Zhang Y, Zhang W, Zhou M . Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona. J Control Release. 2020; 320:1-18. DOI: 10.1016/j.jconrel.2020.01.007. View

Lim J, Jeon S, Shin H, Kim M, Seong Y, Lee W . Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020; 35(6):e79. PMC: 7025910. DOI: 10.3346/jkms.2020.35.e79. View

Skehel J, Hay A, Armstrong J . On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol. 1978; 38(1):97-110. DOI: 10.1099/0022-1317-38-1-97. View

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Hilgenfeld R . From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014; 281(18):4085-96. PMC: 7163996. DOI: 10.1111/febs.12936. View

Singh Malik Y, Kumar N, Sircar S, Kaushik R, Bhat S, Dhama K . Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective. Pathogens. 2020; 9(7). PMC: 7400054. DOI: 10.3390/pathogens9070519. View

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

10.

Gao J, Hu S . Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Biosci Trends. 2020; 14(2):156-158. DOI: 10.5582/bst.2020.03072. View

11.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

12.

Shannon A, Le N, Selisko B, Eydoux C, Alvarez K, Guillemot J . Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020; 178:104793. PMC: 7151495. DOI: 10.1016/j.antiviral.2020.104793. View

13.

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

14.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

15.

Khalili J, Zhu H, Mak N, Yan Y, Zhu Y . Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol. 2020; 92(7):740-746. PMC: 7228408. DOI: 10.1002/jmv.25798. View

16.

Mousavi S, Shah J, Giang H, Al-Ahdal T, Zahid S, Temory F . The first COVID-19 case in Afghanistan acquired from Iran. Lancet Infect Dis. 2020; 20(6):657-658. PMC: 7271037. DOI: 10.1016/S1473-3099(20)30231-0. View

17.

Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H . Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020; 92(6):595-601. PMC: 7228221. DOI: 10.1002/jmv.25726. View

18.

Shiraki K, Daikoku T . Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209:107512. PMC: 7102570. DOI: 10.1016/j.pharmthera.2020.107512. View

19.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

20.

De Clercq E, Li G . Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016; 29(3):695-747. PMC: 4978613. DOI: 10.1128/CMR.00102-15. View